Modafinil Placebo

DRUG4 trials

Sponsors

Takeda, Duke University, Merck Sharp & Dohme LLC

Conditions

HealthyHealthy VolunteersHypersomniaLong COVIDLong COVID-19NarcolepsySleep Disturbance

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

CompletedNCT03522506

TakedaHealthy Volunteers

Start: 2018-05-09End: 2018-11-07Updated: 2021-03-26

A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)

CompletedNCT06619665

Merck Sharp & Dohme LLCHealthy, Narcolepsy

Start: 2024-03-19End: 2024-07-16Updated: 2024-10-01

Phase 2

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

CompletedNCT06404099

Duke UniversityHypersomnia, Long COVID, Long COVID-19

Start: 2024-08-12End: 2026-04-20Updated: 2026-06-03

RECOVER-SLEEP: Platform Protocol

CompletedNCT06404086

Duke UniversityHypersomnia, Long COVID, Long COVID-19 +1

Start: 2024-07-31End: 2025-12-31Updated: 2026-01-22

Related Papers

Orexin 2 receptor‐selective agonist danavorexton (<scp>TAK</scp>‐925) promotes wakefulness in non‐human primates and healthy individuals

Journal of Sleep Research2023-03-1926 citations